#1 Clinical Trials Search in Europe

Diacerein

Diacerein is a medication that has been the subject of several clinical trials, investigating its effectiveness in treating various medical conditions. These trials have primarily focused on its use in osteoarthritis, particularly of the knee and hip, as well as its potential benefits in other areas such as ocular surface disease and type 2 diabetes. Researchers have been exploring diacerein’s anti-inflammatory properties and its ability to inhibit interleukin-1, a key factor in the progression of certain diseases.

Table of Contents

What is Diacerein?

Diacerein is a medication primarily used to treat osteoarthritis, a common joint condition that causes pain and stiffness. It belongs to a class of drugs known as anthraquinones and has anti-inflammatory properties[1]. Diacerein is also known by several other names, including Artrodar, Artifit, and Acert[2].

Conditions Treated with Diacerein

Diacerein is primarily used to treat the following conditions:

  • Osteoarthritis: This is the main condition for which diacerein is prescribed. It’s particularly used for osteoarthritis of the knee and hip[1][3][4].
  • Hand Osteoarthritis: Some studies have investigated the use of diacerein for osteoarthritis affecting the hands[5].
  • Ocular Surface Disease: Research is being conducted to evaluate diacerein’s effectiveness in treating dry eye conditions in patients with degenerative arthritis[6].

How Diacerein Works

Diacerein works differently from typical pain relievers. Its main mechanism of action involves:

  • Interleukin-1 (IL-1) Inhibition: Diacerein inhibits a protein called interleukin-1 beta (IL-1β), which plays a fundamental role in osteoarthritis and cartilage destruction[1].
  • Anti-inflammatory Effects: By inhibiting IL-1β, diacerein helps reduce inflammation in the joints[7].
  • Cartilage Protection: Unlike some pain medications that may accelerate cartilage degeneration, diacerein may help slow down the progression of joint damage[1].

Dosage and Administration

The typical dosage and administration of diacerein may vary depending on the specific condition and the prescriber’s instructions. However, based on the clinical trials reviewed:

  • The usual starting dose is 50 mg once daily, often taken with meals[8].
  • After an initial period (often 2-4 weeks), the dose may be increased to 50 mg twice daily[8][5].
  • Diacerein is typically available in capsule or tablet form[9].

Always follow your doctor’s instructions regarding dosage and administration.

Effectiveness of Diacerein

Several studies have investigated the effectiveness of diacerein:

  • Pain Relief: Diacerein has shown analgesic (pain-relieving) efficacy comparable to diclofenac, a commonly used pain medication, in patients with knee osteoarthritis[1].
  • Joint Space Preservation: A long-term study (ECHODIAH) evaluated diacerein’s ability to slow the decrease in joint space width in hip osteoarthritis patients[4].
  • Symptom Improvement: Studies have used various measures such as the WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) score and visual analog scale (VAS) for pain to assess diacerein’s effectiveness in improving osteoarthritis symptoms[3][10].

Potential Side Effects

While diacerein is generally well-tolerated, it may cause some side effects. The most commonly reported side effect is:

  • Gastrointestinal Issues: Some patients may experience digestive system effects. Studies have specifically monitored for gastrointestinal side effects[10].

Always discuss potential side effects with your healthcare provider.

Ongoing Research and Future Potential

Researchers are exploring additional uses for diacerein beyond osteoarthritis treatment:

  • Diabetes Management: Studies are investigating diacerein’s potential to improve glycemic control in patients with type 2 diabetes[8][2].
  • Non-alcoholic Fatty Liver Disease: Research is examining whether diacerein can help reduce liver fat in patients with type 2 diabetes[2].
  • Ocular Surface Disease: A study is evaluating diacerein’s effectiveness in treating dry eye conditions[6].

These ongoing studies may reveal new potential uses for diacerein in the future, expanding its therapeutic applications beyond osteoarthritis treatment.

Aspect Details
Primary Conditions Studied Osteoarthritis (knee, hip, hand), Ocular Surface Disease, Type 2 Diabetes
Mechanism of Action Anti-inflammatory, Interleukin-1 inhibitor
Common Dosages 50 mg once or twice daily, often with dose escalation
Key Outcome Measures Pain reduction, Joint space measurement, Glycemic control, Inflammatory markers
Study Designs Randomized controlled trials, Bioequivalence studies, Observational studies
Duration of Studies Ranging from 2 months to 3 years
Unique Applications Ocular surface disease in arthritis, Metabolic control in diabetes
Safety Considerations Long-term use in elderly patients, Liver function monitoring

FAQ

  • What is diacerein primarily used for in clinical trials? Diacerein is primarily studied for its potential in treating osteoarthritis, especially of the knee and hip. It's also being investigated for other conditions like ocular surface disease and type 2 diabetes.
  • How does diacerein work in the body? Diacerein works as an anti-inflammatory agent by inhibiting interleukin-1, a protein involved in inflammation. It also has effects on other inflammatory mediators and may help slow down cartilage destruction in osteoarthritis.
  • What are some of the outcomes measured in diacerein clinical trials? Common outcomes measured include pain reduction (using scales like WOMAC or VAS), joint space measurement, glycemic control in diabetes studies, and various inflammatory markers in the body.
  • Are there any unique applications of diacerein being studied? Yes, some unique applications include its potential effect on ocular surface disease in arthritis patients and its possible role in improving metabolic control in type 2 diabetes patients.
  • What is the typical dosage of diacerein used in clinical trials? The dosage varies, but many trials use 50 mg once or twice daily. Some studies start with a lower dose and increase it over time, such as 50 mg once daily for the first month, then 50 mg twice daily thereafter.

Ongoing Clinical Trials on Diacerein

  • Study on Diacerein 1% Ointment for Treating Generalized Epidermolysis Bullosa Simplex in Patients Aged 6 Months and Older

    Recruiting

    4 1
    Investigated drugs:
    Austria Belgium France Greece Ireland Italy +2

Glossary

  • Osteoarthritis: A common joint disorder characterized by the breakdown of joint cartilage and underlying bone, often causing pain and stiffness.
  • Interleukin-1 (IL-1): A type of protein (cytokine) involved in the body's immune response and inflammation processes.
  • WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index, a widely used set of standardized questionnaires to evaluate the condition of patients with osteoarthritis of the knee and hip.
  • VAS: Visual Analogue Scale, a measurement instrument for subjective characteristics or attitudes that cannot be directly measured, often used to assess pain.
  • Bioequivalence: The absence of a significant difference in the rate and extent at which the active ingredient becomes available at the site of drug action when comparing two pharmaceutically equivalent products.
  • HbA1c: Glycated hemoglobin, a form of hemoglobin used to test average blood glucose levels over a period of months, commonly used in diabetes management.
  • Ocular Surface Disease: A group of disorders that affect the surface of the eye, including conditions like dry eye syndrome.
  • Schirmer Test: A procedure to measure the production of tears, used in diagnosing dry eye conditions.
  • NSAID: Non-Steroidal Anti-Inflammatory Drug, a class of medications that reduce pain, decrease fever, and in higher doses decrease inflammation.
  • Cytokine: Small proteins important in cell signaling, particularly in immune responses and inflammation.

References

  1. https://clinicaltrials.gov/study/NCT01120015
  2. https://clinicaltrials.gov/study/NCT02242149
  3. https://clinicaltrials.gov/study/NCT00445276
  4. https://clinicaltrials.gov/study/NCT00451360
  5. https://clinicaltrials.gov/study/NCT00685542
  6. https://clinicaltrials.gov/study/NCT04351100
  7. https://clinicaltrials.gov/study/NCT00440661
  8. https://clinicaltrials.gov/study/NCT02177643
  9. https://clinicaltrials.gov/study/NCT06308068
  10. https://clinicaltrials.gov/study/NCT01906801